Victoria Wang is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Parnassus Ave
M1286
San Francisco, CA 941431270
Telephone
415-476-0584Registry record last updated 23 Oct 2012.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20251 payment
- Dr.Reddy's Laboratories,Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52%Kinase inhibitor52%Tagrisso100%Part D<11 patientsMetabolism & gastrointestinal
48%Serotonin-3 Receptor Antagonist48%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Mechanistic Dissection and Modulation of Cytoskeletal Regulation to Overcome Innate Resistance to KRAS Inhibition
University of California, San Francisco
FY2026$375,150R01CA304896 - Investigating the role of NGN3 in Notch signaling repression during pancreatic endocrinogenesis
Children'S Hospital of Los Angeles
FY2026$47,789F31DK143749 - Mechanistic Dissection and Modulation of Cytoskeletal Regulation to Overcome Innate Resistance to KRAS Inhibition
University of California, San Francisco
FY2025$375,150R01CA304896
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”